AbbVie, Bristol-Myers, Gilead sales and marketing update

The guidance recommends Daklinza with Sovaldi in patients with significant fibrosis and without cirrhosis for untreated HCV genotype 1; previously treated genotype 1 or 4; and genotype 1, 3 or 4 for patients who are interferon ineligible or intolerant. The guidance recommends Daklinza plus peginterferon alfa and ribavirin for HCV genotype 4 with significant fibrosis or cirrhosis in untreated or previously treated patients. For patients who are interferon ineligible or intolerant, the guidance recommends Daklinza plus Sovaldi, with or without ribavirin for HCV genotype 1 or 4 with cirrhosis, and the guidance recommends Daklinza plus Sovaldi with ribavirin in HCV genotype 3 with cirrhosis.

The guidance recommends Viekirax with AbbVie’s Exviera with ribavirin in HCV genotype 1a patients with or without cirrhosis and in genotype 1b patients with compensated cirrhosis. The guidance recommends Viekirax with Exviera in genotype 1b patients without cirrhosis. The guidance recommends Viekirax with ribavirin in HCV genotype 4 patients with or without cirrhosis. All Viekirax recommendations are for previously treated or untreated patients. ...